Read More Pharma Industry News Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline? Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today! bySoujanya RaviJune 25, 2026